proposed the term 'insulin resistance syndrome'. Since then there has been a long-standing debate about how to define this syndrome, [5] [6] [7] [8] [9] definitions being based on components and cut-off points based on expert consensus rather than on evidence-based outcomes. A common feature of the World Health Organization (WHO), 5 the National Heart, Lung, and Blood Institute/American Heart Association (NHLB/AHA), 6 and the International Diabetes Federation (IDF) 7 definitions is that all include subjects with diabetes, while the European Groups for the Study of Insulin Resistance (EGIR) 8 definition is based on hyperinsulinemia. Comparing epidemiological and clinical studies on the MetS is thus difficult because of the many definitions involved. Nevertheless, a few meta-analyses were attempted which revealed that, in the general population, persons with MetS have about twice the risk of CVD, 10, 11 regardless of which definition is used, 12 between three to five-fold risk of type 2 diabetes 13, 14 and one and a half times the risk of mortality from all causes. 11 Different attempts to understand the complex interactions among the components of the MetS have led to considerable progress on its understanding in the past few years, but the pathophysiology of the MetS remains far from clear. The main issue still debated is whether the MetS develops from insulin resistance or from obesity. With respect to the genetic origin some genomewide association studies suggested little evidence supporting a common genetic trait linking dyslipidemia with the other traits of the syndrome. 15 Among the many issues that still deserve focused attention are: (a) to disentangle the predictive value of each component in identifying subjects at higher risk of type 2 diabetes and/or CVD; (b) whether the risk associated with the MetS is superior to the risk associated with the combination of its individual components; (c) how much their clustering increases the risk in an additive or multiplicative way; 16 and (d) whether MetS predicts CVD better than other risk prediction tools such as the Framingham scale. 17 To tackle these issues a factorial analysis approach is needed in which all the components of the syndrome are included as continuous variables, 17 whereas if a definition approach as to having or not having MetS is taken, a cut-off point analysis for each component is to be chosen which implies different cut-off points for men and women and for different ethnic groups. In particular, it has been debated that the increased risk conferred by MetS is mainly due to diabetes, which is present in a large number of people with MetS, and hence diabetes would predict cardiovascular events better than the whole syndrome. This is the question that was posed by Cavallari and colleagues 18 from Boston in this issue of the journal. They present a longitudinal analysis of 13,026 postacute coronary patients (median follow-up 2.5 years) with the aim of establishing the incremental prognostic value of MetS, defined as per the 2005 IDF criteria, of the risk of recurrent major coronary events (MACE). The question therefore remains as to whether the MetS Department of Health, Barcelona, Spain is a prognostic rather than a causal factor. The study is a post-hoc analysis conducted with data from the SOLID-TIMI trial 19 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52; ClinicalTrials.gov NCT 01000727). This is a randomised double-blind placebo controlled trial studying the efficacy and safety of darapladib (160 mg/once daily), a selective drug inhibitor of the lipoproteinassociated phospholipase A2 (Lp-PLA2) enzyme, when added to a background of optimal medical therapy within 30 days of hospitalisation for an acute coronary syndrome. This trial recruited patients from 868 sites in 36 countries. The study found that 61.6% of coronary patients had the MetS, 34.7% had diabetes and 29.3% had both. The presence of MetS increased the risk of MACE (adjusted hazard ratio (HR) 1.29, P < 0.0001) and recurrent myocardial infarction (MI) (adjusted HR 1.30, P < 0.0001). Of the individual components of the MetS, only diabetes, impaired glucose tolerance test and hypertension were significant predictors of MACE. However, in non-diabetic patients, MetS was not significantly associated with the risk of MACE. Conversely, diabetes was a strong independent predictor of MACE in the absence of MetS. This means that MetS had only incremental value to predict recurrent cardiovascular events when the presence or absence of diabetes is established.
The design of this study 18 merits close attention because it is not a pure secondary prevention observational study, but it builds on both arms of the SOLID-TIMI trial, in which half of the patients had been randomly assigned to take darapladib. Selective inhibition of Lp-PLA2 reduces enzyme activity in plasma and in human atheroesclerotic plaques. Lp-PLA2 is produced by inflammatory cells, is transported on circulating low-density lipoprotein (LDL) and hydrolyses oxidised phospholipids in LDL. Part of the secreted enzyme is associated with the phospholipid half of HDL, but this association is poorly understood. Lp-PLA2 contributes to plaque instability through inflammation pathways. Although the results of the SOLID-TIMI trial were negative and did not reduced the risk of MACE after an acute coronary syndrome, 19 darapladib is still a drug that could have potential known or unknown effects on the lipid components of the MetS hence affecting its association with future coronary events. To overcome this possibility, Cavallari and colleagues performed a sensitivity analysis based on the placebo arm of the trial only, and this analysis confirmed the overall results of study. 18 A second point to consider is the fact that some of the individual components of MetS in this study did not show an association with MACE. 18 This might be due to the design of the study. For example, more than 80% of coronary patients from both arms of the SOLID-TIMI trial were on a background recommended guideline therapy including aspirine, blood pressure-lowering agents and statins, of which 43.4% were high potency statins. 19 It can not be excluded that this widespread treatment might have attenuated the observed association between certain individual components of the MetS and MACE risk, such as tryglicerides and HDL-cholesterol, which were not significant in this study (Figure 2) . 18 Furthermore, it could have attenuated the association of the MetS as a whole with cardiovascular end-points in the absence of diabetes (Figures 3 and 4) . 18 Likewise, the absence of an association of the abdominal obesity component with MACE, could have been due to a high geographical variability given the multiple sites involved in the study, especially depending on whether abdominal obesity was assessed as clinical history or as an actual waist measurement.
Another aspect that needs attention is that recruitment into SOLID-TIMI required participants to have at least one additional predictor of cardiovascular risk, among which there was history of MI prior to the qualifying event or polyvascular disease (including carotid or peripheral arterial disease). These prior probabilities could have differentially modified the magnitude of the hazard ratios observed, inasmuch as patients with previous MI carry a higher risk of future MACE and patients with previous MI or polyvascular disease are more likely to have diabetes. However, the authors elegantly showed in an additional analysis that the overall results were consistent irrespective of a history of MI.
Previous studies on the association of MetS and coronary heart disease in coronary patients, or in patients undergoing percutaneous coronary intervention presented conflicting results. Some studies confirmed a predictive role of MetS in the risk of MACE and others did not, 18, 20 while other studies proved that both the MetS and insulin resistance were strong and mutually independent predictors of vascular risk among angiographed coronary patients. 21 Of note are the facts that this study demonstrates an increased risk of MetS in coronary patients, especially those with diabetes, in spite of being under recommended guideline cardiovascular therapy and that only a third of coronary patients were free of MetS or diabetes. These facts lead us to emphasise the need for lifestyle interventions beyond recommended guideline pharmacological treatments in these types of patients. Several randomised trials have demonstrated a benefit of lifestyle, diet and weight interventions in preventing or controlling diabetes. [22] [23] [24] Furthermore, recent evidence from a trial at the primary care level shows promising results in reducing body weight and type 2 diabetes. 25 It would be of interest to test if weight reduction interventions in established coronary patients could lead to similar results in preventing recurrent cardiovascular events. 26 An emerging new lifestyle intervention to control the MetS pointing towards the same favourable direction as the aforementioned trials is the practice of yoga. A recent meta-analysis 27 on its effects on MetS demonstrated, although with some limitations, that when yoga supplemented standard medication in coronary patients, an additional statistically significant benefit was observed in reducing cardiovascular risk factors, when compared with patient controls who did not practice any physical exercise. Although yoga was, however, not superior to the routine practice of traditional aerobic exercise, it is a form of physical exercise that might be more attractive to older patients, or patients with osteo-articular limitations to practice other forms of exercise.
It is likely that the global prevalence of MetS will increase in the years to come if the growing global epidemic of obesity continues, due to a worldwide increase of caloric intake and decrease of physical activity. 28 The prevalence of MetS in many countries ranges on average between 20% and 30% of the population as a whole, 29 but it increases greatly with age and there are also gender differences. 12 MetS prevalence in coronary patients reflects in a certain way the underlying distribution of the MetS of the populations from where they come. From the public health point of view efforts to intervene to move the distribution of body mass index and other risk factors in the population as a whole, as well as in cardiovascular patients, should continue to be a high priority.
In conclusion, the study by Cavallari et al. 18 confirms that MetS confers an increased risk of future MACE and all-cause mortality in already established coronary patients. What this study adds to current evidence is that in coronary patients with diabetes, the incremental risk of MetS for MACE was not greater than with diabetes alone. This confirms the findings of a population cohort study showing that not only diabetes but also hypertension were similar predictors of CVD mortality as MetS. 30 It would be of interest to examine if analogous results could be replicated in population cohorts from other parts of the world.
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